After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...
Let me now turn the call over to Marion. Thank you, George. Regeneron's fourth quarter performance demonstrates our ongoing leadership across therapeutic categories. Our commercial team is well ...
which are ideal for extracellular targets and those on the cell surface,” said George Yancopoulos, president and chief scientific officer of Regeneron. “Through the RGC and our other research ...
enabling Regeneron to accelerate the development of innovative genetic therapies and a rich pipeline of hearing loss treatments," said George Yancopolous, Regeneron's chief scientific officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback